Theravance Biopharma, Inc. Restructuring Charges
Theravance Biopharma, Inc. (TBPH) reported Restructuring Charges of $2.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-11
- Theravance Biopharma, Inc. restructuring charges for the quarter ending 2026-06-30 was $2.18M.
- Theravance Biopharma, Inc. restructuring charges for the quarter ending 2026-03-31 was $2.60M.
- Theravance Biopharma, Inc. restructuring charges for the quarter ending 2023-12-31 was $0.00.
- Theravance Biopharma, Inc. restructuring charges for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Theravance Biopharma, Inc. restructuring charges for fiscal 2023 was $2.74M, a 78.63% decline from fiscal 2022.
- Theravance Biopharma, Inc. restructuring charges for fiscal 2022 was $12.84M, a 36.26% decline from fiscal 2021.
- Theravance Biopharma, Inc. restructuring charges for fiscal 2021 was $20.14M.
| Period end | Restructuring Charges 1 month | Restructuring Charges 3 month | Restructuring Charges 3 month as first filed | Restructuring Charges 6 month | Restructuring Charges 6 month as first filed | Restructuring Charges 7 month | Restructuring Charges 9 month | Restructuring Charges 9 month as first filed | Restructuring Charges 10 month | Restructuring Charges 12 month | Restructuring Charges 13 month |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.18M 10-Q · filed 2026-08-11 | $4.78M 10-Q · filed 2026-08-11 | |||||||||
| 2026-03-31 | $2.60M 10-Q · filed 2026-05-07 | ||||||||||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | ||||||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $0.00 derived: sum of 2 quarters · filed 2025-03-07 | $1.17M derived: sum of 3 quarters · filed 2025-03-07 | $2.74M 10-K · filed 2025-03-07 | |||||||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-14 | $1.17M derived: sum of 2 quarters · filed 2024-11-14 | $2.74M 10-Q · filed 2024-11-14 | $2.74M derived: sum of 4 quarters · filed 2024-11-14 | |||||||
| 2023-06-30 | $1.17M 10-Q · filed 2024-08-08 | $2.74M 10-Q · filed 2024-08-08 | $2.74M derived: sum of 3 quarters · filed 2024-08-08 | $3.25M derived: sum of 4 quarters · filed 2024-08-08 | |||||||
| 2023-03-31 | $1.57M 10-Q · filed 2024-05-15 | $1.57M derived: sum of 2 quarters · filed 2024-05-15 | $2.08M derived: sum of 3 quarters · filed 2024-05-15 | $5.09M derived: sum of 4 quarters · filed 2024-05-15 | |||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $509.00K derived: sum of 2 quarters · filed 2024-03-01 | $3.51M derived: sum of 3 quarters · filed 2024-03-01 | $12.84M 10-K · filed 2024-03-01 | |||||||
| 2022-09-30 | $33.00M 10-K · filed 2024-03-01 | $509.00K 10-Q · filed 2023-11-09 | $3.51M derived: sum of 2 quarters · filed 2023-11-09 | $12.84M 10-Q · filed 2023-11-09 | $11.43M 10-Q · filed 2022-11-09 | $31.21M derived: sum of 4 quarters · filed 2023-11-09 | $31.60M 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $3.00M 10-Q · filed 2023-08-09 | $1.59M 10-Q · filed 2022-08-08 | $12.33M 10-Q · filed 2023-08-09 | $10.92M 10-Q · filed 2022-08-08 | $30.70M derived: sum of 3 quarters · filed 2023-08-09 | $31.10M 10-Q · filed 2022-08-08 | $32.47M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $9.32M 10-Q · filed 2023-05-10 | $27.70M derived: sum of 2 quarters · filed 2023-05-10 | $29.50M 10-Q · filed 2022-05-06 | $29.47M derived: sum of 3 quarters · filed 2023-05-10 | |||||||
| 2021-12-31 | $18.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $20.14M derived: sum of 2 quarters · filed 2023-03-01 | $20.14M 10-K · filed 2023-03-01 | ||||||||
| 2021-09-30 | $1.77M 10-Q · filed 2022-11-09 | $1.77M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |